Matthew P. Goetz

32.9k total citations · 5 hit papers
297 papers, 11.0k citations indexed

About

Matthew P. Goetz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Matthew P. Goetz has authored 297 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 176 papers in Oncology, 114 papers in Pulmonary and Respiratory Medicine and 104 papers in Cancer Research. Recurrent topics in Matthew P. Goetz's work include Advanced Breast Cancer Therapies (93 papers), Estrogen and related hormone effects (76 papers) and Breast Cancer Treatment Studies (73 papers). Matthew P. Goetz is often cited by papers focused on Advanced Breast Cancer Therapies (93 papers), Estrogen and related hormone effects (76 papers) and Breast Cancer Treatment Studies (73 papers). Matthew P. Goetz collaborates with scholars based in United States, Japan and United Kingdom. Matthew P. Goetz's co-authors include James N. Ingle, Matthew M. Ames, Roberto A. Leon‐Ferre, Vera J. Suman, Masakazu Toi, Fergus J. Couch, Susana Barriga, Charles Erlichman, Stephanie L. Safgren and Carol Reynolds and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Matthew P. Goetz

278 papers receiving 10.8k citations

Hit Papers

MONARCH 3: Abemaciclib As Initial Th... 2005 2026 2012 2019 2017 2005 2019 2023 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
    2017 1.1k citations Matthew P. Goetz, Jens Huober et al. Journal of Clinical Oncology profile →
  2. Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes
    2005 567 citations Matthew P. Goetz, Vera J. Suman et al. Journal of Clinical Oncology profile →
  3. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
    2019 407 citations Stephen Johnston, Matthew P. Goetz et al. profile →
  4. Advances in systemic therapies for triple negative breast cancer
    2023 259 citations Roberto A. Leon‐Ferre, Matthew P. Goetz profile →
  5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
    2018 237 citations Matthew P. Goetz, Matthias Schwab et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew P. Goetz United States 48 5.6k 3.5k 3.1k 2.7k 2.3k 297 11.0k
Gini F. Fleming United States 60 8.2k 1.5× 2.7k 0.8× 3.7k 1.2× 4.1k 1.5× 1.7k 0.8× 334 16.6k
Shinzaburo Noguchi Japan 64 6.1k 1.1× 2.8k 0.8× 5.2k 1.7× 5.1k 1.9× 2.5k 1.1× 389 13.7k
Sjoerd Rodenhuis Netherlands 60 6.0k 1.1× 4.3k 1.2× 3.4k 1.1× 3.6k 1.3× 804 0.4× 253 12.8k
Sabine C. Linn Netherlands 48 4.7k 0.8× 2.4k 0.7× 3.4k 1.1× 3.2k 1.2× 1.5k 0.7× 231 9.1k
Paul E. Goss United States 47 5.4k 1.0× 2.1k 0.6× 3.8k 1.2× 2.3k 0.8× 3.7k 1.6× 214 10.6k
G. Milano France 57 7.8k 1.4× 3.1k 0.9× 1.5k 0.5× 4.1k 1.5× 527 0.2× 392 12.3k
William D. Figg United States 52 3.1k 0.6× 3.8k 1.1× 2.4k 0.8× 4.6k 1.7× 811 0.4× 234 10.3k
Jungsil Ro South Korea 52 7.9k 1.4× 5.3k 1.5× 3.6k 1.2× 3.5k 1.3× 976 0.4× 189 13.3k
P. Fumoleau France 61 9.6k 1.7× 2.7k 0.8× 4.4k 1.4× 3.3k 1.2× 697 0.3× 326 14.3k
Karen N. Price Switzerland 50 5.8k 1.0× 1.9k 0.6× 4.9k 1.6× 1.4k 0.5× 2.6k 1.1× 103 9.1k

Countries citing papers authored by Matthew P. Goetz

Since Specialization
Citations

This map shows the geographic impact of Matthew P. Goetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew P. Goetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew P. Goetz more than expected).

Fields of papers citing papers by Matthew P. Goetz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew P. Goetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew P. Goetz. The network helps show where Matthew P. Goetz may publish in the future.

Co-authorship network of co-authors of Matthew P. Goetz

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew P. Goetz. A scholar is included among the top collaborators of Matthew P. Goetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew P. Goetz. Matthew P. Goetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mürdter, Thomas E., Werner Schroth, Matthew P. Goetz, et al.. (2025). Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clinical Cancer Research. 31(23). 4903–4911.
2.
Goetz, Matthew P., Grace M. Choong, Tanya L. Hoskin, et al.. (2025). Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”. Journal of Clinical Oncology. 43(30). 3323–3324.
3.
Geist, Felix, Xiaojia Tang, Krishna R. Kalari, et al.. (2024). Identification of a Notch transcriptomic signature for breast cancer. Breast Cancer Research. 26(1). 4–4. 4 indexed citations
4.
Koch, R., Nicholas Boddicker, Joon Chae Na, et al.. (2024). 353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Annals of Oncology. 35. S364–S364. 1 indexed citations
5.
Damodaran, Senthil, Massimo Cristofanilli, Matthew P. Goetz, et al.. (2024). Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study. Cancer Research. 84(9_Supplement). PO2–14. 1 indexed citations
6.
Loi, Sherene, Stephen Johnston, Carlos L. Arteaga, et al.. (2024). Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).. Journal of Clinical Oncology. 42(17_suppl). LBA507–LBA507. 12 indexed citations
7.
Choong, Grace M., Tanya L. Hoskin, Judy C. Boughey, James N. Ingle, & Matthew P. Goetz. (2024). The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 513–513. 5 indexed citations
8.
O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations
9.
10.
Tang, Xiaojia, Kevin J. Thompson, Krishna R. Kalari, et al.. (2023). Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors. Breast Cancer Research. 25(1). 57–57. 2 indexed citations
11.
Yu, Jia, Yongxian Zhuang, Xiaoyang Fan, et al.. (2022). Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. Cancers. 14(17). 4220–4220. 11 indexed citations
12.
Zhou, Qin, Xinyi Tu, Qian Zhu, et al.. (2021). Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. Cancer Research. 81(12). 3333–3346. 30 indexed citations
13.
Reid, Joel M., et al.. (2021). Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology. 162(12). 19 indexed citations
14.
Haddad, Tufia C., J. Helgeson, Anita M. Preininger, et al.. (2021). Accuracy of an Artificial Intelligence System for Cancer Clinical Trial Eligibility Screening: Retrospective Pilot Study. JMIR Medical Informatics. 9(3). e27767–e27767. 39 indexed citations
15.
Carter, Jodi M., Mei‐Yin C. Polley, Roberto A. Leon‐Ferre, et al.. (2021). Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer. Clinical Cancer Research. 27(20). 5628–5637. 35 indexed citations
16.
Yu, Jia, Bo Qin, Ann M. Moyer, et al.. (2020). Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research. 30(7). 590–601. 71 indexed citations
17.
Shee, Kevin, Matthew Ung, Nicole A. Traphagen, et al.. (2019). A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition. Clinical Cancer Research. 26(1). 159–170. 1 indexed citations
18.
Tu, Xinyi, Mohamed M. Kahila, Qin Zhou, et al.. (2018). ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 17(11). 2462–2472. 71 indexed citations
19.
Ingle, James N., Fang Xie, Matthew J. Ellis, et al.. (2016). Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research. 76(23). 7012–7023. 43 indexed citations
20.
Ingle, James N., Mohan Liu, D. Lawrence Wickerham, et al.. (2013). Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery. 3(7). 812–825. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gini F. Fleming Breakdown of academic impact, for papers by Shinzaburo Noguchi Breakdown of academic impact, for papers by Sjoerd Rodenhuis Breakdown of academic impact, for papers by Sabine C. Linn Breakdown of academic impact, for papers by Paul E. Goss Breakdown of academic impact, for papers by G. Milano Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Jungsil Ro Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Karen N. Price
Rankless by CCL
2026